Phase i combination study of trabectedin and capecitabine in patients with advanced malignancies

Investigational New Drugs

Volumn 30, Issue 5, 2012, Pages 1942-1949

  Gore, Lia ^a   Rivera, E ^b   Basche, M ^a   Moulder Thompson, S L ^b   Li, J ^c   Eppers, S ^a   Grolnic, S ^a   O'Bryant, C ^a   Cleere, D ^d   Elsayed, Y A ^c   Eckhardt, S G ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^d HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Advanced malignancy; Capecitabine; Pharmacokinetics; Phase I; Trabectedin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; BILIRUBIN; CAPECITABINE; FLUOROURACIL; TRABECTEDIN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILE DUCT CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CHOLESTASIS; DEHYDRATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAINTNESS; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; HUMAN CELL; HYPOKALEMIA; HYPOPHOSPHATEMIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; PANCREATITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; STOMATITIS; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DIOXOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; TETRAHYDROISOQUINOLINES; YOUNG ADULT;

EID: 84867775658     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9747-9     Document Type: Article

References (45)

1. Pommier Y, Kohlhagen G, Bailly C, et al. (1996) DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 35:13303-13309
2. Moore BM, Seaman FC, Wheelhouse RT, Hurley LH (1998) Mechanism for the catalytic activation of ecteinascidin 743 and its subsequent alkylation of guanine N2. J Am Chem Soc 120:2490-2491
3. Zewail-Foote M, Hurley LH (1999) Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem 42:2493-2497
4. Minuzzo M, Marchini S, Broggini M, et al. (2000) Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci U S A 97:6780-6784
5. Takebayashi Y, Pourquier P, Zimonjic DB, et al. (2001) Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 7:961-966
6. Damia G, Silvestri S, Carrassa L, et al. (2001) Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Canc 92:583-588
7. Barthomeuf C, Bourguet-Kondracki ML, Kornprobst JM (2008) Marine metabolites overcoming or circumventing multidrug resistance mediated by ATP-dependent transporters: a new hope for patient with tumors resistant to conventional chemotherapy. Anti Canc Agents Med Chem 8:886-903
8. Vincenzi B, Napolitano A, Frezza A, et al. (2010) Wide spectrum characterization of trabectedin: biology, clinical activity and future perspectives. Pharmacogenomics 11:865-878
9. Li WW, Takahashi N, Jhanwar S, et al. (2001) Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. Clin Canc Res 7:2908-2911
10. Scotlandi K, Perdichizzi S, Manara MC, et al. (2002) Effectiveness of ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells. Clin Canc Res 8:3893-3903
11. Izbicka E, Lawrence R, Raymond E, et al. (1998) In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann Oncol 9:981-987
12. Valoti G, Nicoletti MI, Pellegrino A, et al. (1998) Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin Canc Res 4:1977-1983
13. Taamma A, Misset JL, Riofrio M, et al. (2001) Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol 19:1256-1265
14. Villalona-Calero MA, Eckhardt SG, Weiss G, et al. (2002) A phase I and pharmacokinetic study of ecteinascidin-743 on a daily × 5 schedule in patients with solid malignancies. Clin Canc Res 8:75-85
15. Ryan DP, Supko JG, Eder JP, et al. (2001) Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Canc Res 7:231-242
16. Delaloge S, Yovine A, Taamma A, et al. (2001) Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patientspreliminary evidence of activity. J Clin Oncol 19:1248-1255
17. Fayette J, Boyle H, Chabaud S, et al. (2010) Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: analysis of 92 patients treated in a single institution. Anti Canc Drugs 21:113-119
18. Zelek L, Yovine A, Brain E, et al. (2006) A phase II study of Yondelis® (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br J Canc 94:1610-1614
19. Yovine A, Riofrio M, Blay JY, et al. (2004) Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 22:890-899
20. Laverdiere C, Kolb EA, Supko JG, et al. (2003) Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer 98:832-840
21. Le Cesne A, Blay JY, Judson I, et al. (2005) Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial. J Clin Oncol 23:576-584
22. Garcia-Carbonero R, Supko JG, Manola J, et al. (2004) Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 22:1480-1490
23. Garcia-Carbonero R, Supko JG, Maki RG, et al. (2005) Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 23:5484-5492
24. Sessa C, De Braud F, Perotti A, et al. (2005) Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 23:1867-1874
25. Michaelson MD, Gilligan T, Oh W, et al. (2005) Phase II study of 3 h, weekly infusion of trabectedin (ET-743) in men with metastatic, androgen-independent prostate carcinoma (AIPC) [abstract]. J Clin Oncol 23:16s, Abstract 4517
26. Morgan JA, Le Cesne A, Chawla S, et al. (2007) Randomized phase II study of trabectedin in patients with liposarcoma and leiomyosarcoma (L-sarcomas) after failure of prior anthracyclines (A) and ifosfamide (I) [abstract]. J Clin Oncol 25:18s, Abstract 10060
27. Krasner CN, McMeekin DS, Chan S, et al. (2007) A phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Canc 97:1618-1624
28. Demetri GD, Chawla SP, von Mehren M, et al. (2009) Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 27:4188-4196
29. 2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Ann Oncol 20:1794-1802
30. Monk BJ, Herzog TJ, Kaye SB, et al. (2010) Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol 28:3107-3114
31. Kaye SB, Colombo N, Monk BJ, et al. (2011) Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval. Ann Oncol 22:48-58
32. Poveda A, Vergote I, Tjulandin S, et al. (2011) Trabectedin plus pegylated liposomal doxorubicin in relpased ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol 22:39-48
33. Takahashi N, Li WW, Banerjee D, et al. (2001) Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin Canc Res 7:3251-3257
34. Meco D, Colombo T, Ubezio P, et al. (2003) Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies. Canc Chemother Pharmacol 52:131-138
35. Messersmith WA, Jimeno A, Ettinger D, et al. (2008) Phase I trial of weekly trabectedin (ED-743) and gemcitabine in patients with advanced solid tumors. Canc Chemother Pharmacol 63:181-188
36. Cohen RB, Schilder RJ, Cheng J, et al. (2005) Final results of a combination study between trabectedin and pegylated liposomal doxorubicin (PLD) in patients with advanced malignancies [abstract]. J Clin Oncol 23:16s, Abstract 3074
37. Blay J-Y, von Mehren M, Samuels BL, et al. (2008) Phase I combination of trabectedin and doxorubicin in patients with soft tissue sarcoma. Clin Canc Res 14:6656-6662
38. Xeloda® (capecitabine) tablets [prescribing information] (2006) Nutley, NJ: Roche Pharmaceuticals
39. Ozer H, Armitage JO, Bennett CL, et al. (2000) 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 18:3558-3585
40. Forouzesh B, Hidalgo M, Denis L, et al. (2001) Phase I and pharmacokinetic study of ET-743, a minor groove DNA binder, administrated weekly to patients with advanced cancer [abstract]. Proc Am Soc Clin Oncol 20:94a, Abstract 373
41. Twelves C, Hoekman K, Bowman A, et al. (2003) Phase I and pharmacokinetic study of Yondelis™ (ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. Eur J Canc 39:1842-1851
42. van Kesteren C, Twelves C, Bowman A, et al. (2002) Clinical pharmacology of the novel marine-derived anticancer agent ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study. Anti Canc Drugs 13:381-393
43. Gurtler JS, Goldstein L, Delprete S, et al. (2005) Trabectedin in third line breast cancer: a multicenter, randomized, phase II study comparing two administration regimens [abstract]. J Clin Oncol 23:16s, Abstract 625
44. McMeekin DS, Manikas G, Crispens M, et al. (2004) A phase II study of trabectedin (ET-743) as a second line therapy in patients with persistent or recurrent endometrial carcinoma [abstract]. J Clin Oncol 22:14s, Abstract 5086
45. Casali PG, Sanfilippo R, D'Incalci M (2010) Trabectidin therapy for sarcomas. Curr Opin Oncol 22:342-346